PVP Ventures has increased its shareholding in 7 Med India Private Limited to 41.23% following the acquisition of an additional 4,263 equity shares. The transaction, completed on July 7, 2026, is part of the company's strategic expansion into the healthcare sector and represents the second tranche of a larger investment plan. The total outlay for the majority shareholding of 50.62% is expected to be around INR 127 crores.

The acquisition was executed in accordance with the Share Purchase Agreement and Shareholders' Agreement between the parties. 7 Med India Private Limited is among the top five organized players in India's renal care sector, offering a comprehensive range of dialysis services across its pan-India network. The company became an associate of PVP Ventures following the first tranche of acquisition on November 4, 2025.

The transaction does not fall within the ambit of a related party transaction and was undertaken on an arm's length basis. No governmental or regulatory approvals were required for this specific acquisition. The consideration for the transaction was paid in cash.

PVP Ventures remains committed to completing the balance acquisition to increase its aggregate stake to 50.62% in the target company. The timeline for the final tranche will be governed by the terms of the definitive agreements already executed between the parties.

Details of Acquisition

PVP Ventures Limited reported a consolidated net loss of ₹319.23 lakh for the quarter ended March 31, 2026, compared to a net loss of ₹256.51 lakh in the corresponding period of the previous year. Total income from operations for the consolidated entity rose to ₹5,393.75 lakh in Q4FY26 from ₹2,179.72 lakh in Q4FY25. For the full year ended March 31, 2026, the company reported a consolidated net loss of ₹996.35 lakh on a total income of ₹11,296.21 lakh.

On a standalone basis, PVP Ventures posted a net profit of ₹628.27 lakh for the quarter, a slight increase from ₹597.89 lakh in the same quarter last year. Standalone total income from operations for Q4FY26 was ₹2,103.43 lakh, up from ₹1,967.56 lakh in Q4FY25. For the fiscal year FY26, standalone net profit was ₹90.99 lakh with total income at ₹5,341.55 lakh.

The Board of Directors approved the financial results at its meeting held on May 29, 2026. The Audit Committee had reviewed the results earlier on the same day. The statutory auditors audited the quarterly results. The company filed these results with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Summary

Earnings per share (EPS) on a consolidated basis for the quarter was a loss of ₹0.25 on a basic and diluted basis. Standalone basic and diluted EPS for the quarter was ₹0.24. The equity share capital remained unchanged at ₹26,040.37 lakh during the period.